This article discusses joint modeling of compliance and outcome for longitudinal studies when noncompliance is present. We focus on two-arm randomized longitudinal studies in which subjects are randomized at baseline, treatment is applied repeatedly over time, and compliance behaviors and clinical outcomes are measured and recorded repeatedly over time. In the proposed Markov compliance and outcome model, we use the potential outcome framework to define pre-randomization principal strata from the joint distribution of compliance under treatment and control arms, and estimate the effect of treatment within each principal strata. Besides the causal effect of the treatment, our proposed model can estimate the impact of the causal effect of the treatment at a given time on future compliance. Bayesian methods are used to estimate the parameters. The results are illustrated using a study assessing the effect of cognitive behavior therapy on depression. A simulation study is used to assess the repeated sampling properties of the proposed model.
Introduction
Because randomized treatment assignment removes both observed and unobserved confounding, randomized studies provide a means to estimate the causal effect of a treatment. However, because patients can choose whether or not to comply with their assigned treatment in many circumstances, noncompliance or partial compliance is very common in the randomized studies. To estimate causal treatment effects, traditional analysis methods include intent-to-treat (ITT) analysis, as-treated (AT) analysis, and per-protocol (PP) analysis. ITT analyses provide a causal estimate of the effect of randomization, which can differ from the causal effect of the treatment in the presence of noncompliance. AT analyses ignore the randomization assignment, and compare the outcomes by using the actual treatment received. PP analyses compare the outcomes for subjects who comply with the assigned treatment. However, because the latter two analysis methods condition on the treatment taken, which is a post-randomization variable, selection bias can affect the AT and PP estimates of the causal effect of treatment [1] .
A large literature has developed in recent years to estimate causal effects via potential outcomes. Under the potential outcome framework, the causal estimands are comparisons of the potential outcomes that would have been observed under all possible assignments of treatments. The idea of describing causal effects in terms of potential outcomes dates back to Neyman in 1923 [2] , and is now becoming widely used in the fields of economics, social and behavioral sciences, epidemiology, and statistics.
In this manuscript, we use the principal stratum approach formulated in [3] . For noncompliance problems, the principal strata are determined by the joint distributions of the compliance behaviors under each treatment arm. In the context of a two-arm randomized trial, they consist of compliers (subjects who take
A Markov compliance and outcome model for longitudinal compliance designs
We focus on the two-arm randomized control trial setting where subjects are randomized at baseline to either treatment or control but then are followed for t D 1; : : : ; T time points after baseline, with the outcome of interest and compliance behavior assessed at each time point t . Our model is designed to focus on two goals, both of which are of clinical interest. Our first goal is to assess the treatment assignment (ITT) effects within principal strata at each time point -in particular the complier average causal effect, corresponding to the ITT effect with the principal stratum in which the treatment taken corresponds with the treatment assigned under both treatment arms. Our second goal, unique in the literature to our knowledge, is to determine how previous compliance behavior and causal effects may impact current compliance behavior. These goals can only be accomplished by considering the joint distribution of the potential outcomes and potential treatment received over all time points.
Notation
For subject i D 1; : : : ; n, we use Z i to denote the randomization assignment (1 for treatment and 0 for control) and x i to denote the baseline covariates. For subject i in the follow-up period t , we use Y i;t .´i / to denote the potential clinical outcomes under treatment assignment Z i D´i , and D i;t .´i / to denote the potential treatment received under treatment assignment Z i D´i . In the context of a two-arm randomized trial without specific restriction, the principal strata consists of compliers, always-takers, not-takers, and defiers:
Thus, the joint distribution of D i;t .1/ and D i;t .0/ fully determines the principal strata S i;t at time t . Because only one of D i;t .1/ or D i;t .0/ is observed, S i;t is latent for all subjects.
Complete data distribution
Under the potential outcome framework, the complete data include all subjects' randomization statuses, principal strata memberships, and potential clinical outcomes under all possible treatment arms in all follow-up periods. The joint distribution of the complete data is given by .0/ Áio :
The three equalities follow respectively from these three assumptions:
(1) Ignorable treatment assignment assumption [10] . This assumption is that assignment is independent of all baseline variables (observed and unobserved) and potential outcomes. Under ignorability, we do not need to model the assignment mechanism. This assumption is reasonable in most clinical trial settings, where treatments are usually assigned at random. (2) Stable unit treatment value assumption [11] .
Stable unit treatment value assumption comprises two subassumptions. The first subassumption is that the potential compliance behavior of one individual is not affected by the randomization status of other individuals, and the potential outcomes of one individual are not affected by the randomization status and the potential compliance behaviors of other individuals. This assumption is reasonable in trials like the CBT study, where the disease (depression) is not infectious, and patients visit their doctors as individuals, instead of in groups. The second subassumption is that there is no 'hidden' version of the treatment, that is, there are no systematic differences in the treatments assigned within the treatment categories. This assumption is reasonable in the CBT study setting, given that care was taken to standardize treatment provided. (3) The longitudinal potential outcomes and principal compliance statuses follow a Markov process with possibly differing orders.
In particular, we assume the potential outcomes at the end of the follow-up period t depend not only on the principal stratification membership at the current time but on the principal strata in previous t 1; : : : ; t K y c follow-up periods as well as on the potential outcomes at the end of previous t 1; : : : ; t K y y follow up periods. Similarly, we assume the principal strata in the follow-up period t depend on the principal strata in previous t 1; : : : ; t K c c follow-up periods and the potential outcomes at the end of previous t 1; : : : ; t K c y follow up periods. (We let K
Parametric submodels
For each of the components in the complete data likelihood, we make the following additional modeling assumptions.
Modeling principal stratum membership at t D 1. We focus on the two-arm randomized trial in which subjects assigned to the control group could not access the treatment; therefore the principal strata only consists of compliers and not-takers. We use probit regression to model the (binary) baseline compliance strata, conditional on subject level baseline covariates
Modeling potential outcomes at t D 1. Conditional on the principal strata in the first follow-up period, we assume the potential outcomes at the end of first follow-up period follow a bivariate normal distribution with correlation . For individual i,
In cross-sectional settings where the causal parameters of interest are non-parametrically identified [12] , estimation of the correlation between the potential outcomes of a given subject is not required and thus is usually ignored; when considered, a location shift between Y i;t .1/ and Y i;t .0/ ( D 1) has sometimes been assumed [13, 14] . Even though only potential outcomes under the arm the subjects actually take are observable, in noncompliance settings where the outcome is binary, the within-correlation is partially identified [15] ; however, in this continuous setting, there will be no data available to estimate this within-subject correlation . Viewing as a sensitivity parameter, we assume a variety of the correlations between 0 and 1. This correlation has little impact when making inferences about ITT effects in large finite populations and no impact on such inference in superpopulations [2] . But in this setting, this correlation may have considerable impact on the estimates of the parameters providing information about the impact of outcomes on compliance.
Modeling principal stratum membership at t > 1. For the principal strata in follow-up period t .t > 1/, we assume a single-order Markov dependence (K . This Markov dependence allows for interactions between the effects of the previous potential outcomes and the compliance class status, and is assumed to be constant over time. Thus, for patient i in the follow-up period t ,
Modeling potential outcomes at t > 1. For the potential outcomes at the end of follow up periods t > 1, we assume a bivariate normal distribution conditional on principal strata and previous potential outcomes with a single-order Markov dependence for the potential outcomes and a zero-order Markov dependence on the principal strata, that is, depending only on the principal strata membership at time t 
Figure 1 provides a graphical summary of the assumed Markovian relationships between the principal strata and the potential outcomes. 
Principal effects
Imbens and Rubin [4] defined the principal effect as the ITT effect of the treatment within each principal compliance stratum. Because of the conditioning structure of our model, we define the principal effects conditional on both the current principal stratum membership and the previous potential outcomes:
The ITT effect within the complier stratum, I T T c , is often termed the complier average causal effect (CACE), because it is the one principal stratum in which the treatment taken corresponds with the treatment assigned under both treatment arms. The ITT effect of the treatment within the not-taker stratum I T T n is often assumed zero in causal models for clinical studies. This is called the exclusion restriction (ER) assumption [12] . This assumption is plausible in many studies, but not always. For example, in the CBT study, the clinical outcome is a subject's depression severity. The not-takers randomized to the cognitive therapy may experience stress as a result of failing to participate in the therapy, and thus become more depressed, but may not be stressed about not participating in the therapy if they were assigned to usual care. Therefore not-takers may develop different levels of depression under different assignments; and thus, the ER assumption may not be met. Our proposed model allows us to estimate the ITT effect within the not-taker stratum, I T T n .
Note that our assumptions about the Markov structure of the model allow us to obtain estimates of within-principal-stratum ITT effects that have a direct causal interpretation. Presence of substantial higher-order Markov relationships suggest that alternative approaches may be required; we provide more detail in Section 5.
Estimation
A Bayesian approach with data augmentation [16] is a natural method to deal with the missing data structure. The posterior distributions of the parameters and full conditional distributions of the missing potential outcomes do not have simple closed forms, so we use a MCMC algorithm. To obtain draws from the posterior distributions of the parameters, a Gibbs sampling algorithm is used forˇ; , and 2 , and Metropolis algorithm is used for˛and Â. A Metropolis algorithm is also used to obtain draws from the full conditional distributions of the missing potential outcomes. For the Metropolis algorithm, we propose random draws from a t distribution with three degrees of freedom. The variance is adjusted to give an acceptance rate of approximately 30% [17] . The detailed descriptions of the posterior distribution of the parameters and the full conditional distributions of missing potential outcomes and missing principal compliance are given in the Appendix. To check convergence, we calculate a measure of between and within-chain variance O R [17] . O R < 1:1 is considered acceptable. In addition to the missing data in the unobserved treatment arm, 19% of subjects have one or more of their BDI outcomes not recorded after time t D 1. We assume a missing at random mechanism for these missing data, so that conditional on the observed outcomes and compliance behavior, missingness is assumed to be random. Thus, for missing outcome at time t > 1, draws from the joint distribution of . 
Model fit assessment
To assess the fit of the data, we consider the posterior predictive distribution (PPD) p-values [17] . Because the principal compliance of subjects randomized to the treatment group are equal to the observed compliance, we compare the PPD of the principal compliances and assess their fit to the observed principal compliances. We make posterior predictive checks of the fitted models by using the percentage of compliers in the treatment as the test statistics, and compare the observed percentage of compliers with their posterior predictive distribution to obtain PPD p values. A PPD p value close to 0.50 indicates good fit of the model to the data.
We use a chi-square type test of the form T D P n i D1 
Application to the cognitive behavioral therapy trial
The CBT study was a randomized longitudinal study designed to test the effectiveness of a suicide prevention treatment [18] . This study was designed to determine whether a brief psychosocial intervention could reduce depression severity over an 18-month follow up interval in a sample of subjects who had attempted suicide. Cognitive therapy was the psychosocial intervention for this study. It is built on clinical investigations regarding the psychopathological characteristics of suicide behaviors. The study sample consisted of 120 individuals who attempted suicide. Individuals were initially identified in the emergency department following a suicide attempt at the Hospital of the University of Pennsylvania. After the subjects were medically cleared or stabilized in the emergency department, they were transferred to the psychiatric emergency department. Eligible individuals were randomized into two groups: the control group, where patients received usual care, and treatment group, where patients were offered outpatient cognitive therapy sessions specifically developed for preventing suicide attempts on a weekly or biweekly basis. The central feature of this psychotherapy was the identification of proximal thoughts, images, and core beliefs that were activated prior to the suicide attempt.
The clinical outcome measure was the beck depression inventory (BDI), which indicated the severity of depression. Subsequent in-person assessments of BDI were conducted at 1, 3, 6, 12, and 18 months following the baseline interview. Among the 120 subjects, 60 subjects were randomly assigned to the cognitive therapy group, and 60 subjects to the usual care group. We restricted our analysis to the 58 subjects in the treatment arm and the 56 subjects in the control arm with at least one BDI follow-up measurement. Subjects' age ranged from 18 to 66 years, and 61% of them are female. Subjects assigned to the CBT arm who met with the doctor to receive CBT at least once during a given follow up period are defined as having successfully received treatment. Table I shows that randomization achieved balance across the observed baseline covariates between two treatment arms. We apply a square root transformation on BDI to improve the normality approximation for the clinical outcomes, and summarize the observed p BDI of the study sample at each follow-up time in Figure 2 . It shows that the subjects randomized to the cognitive therapy group developed less severe depression on average than the subjects randomized to the usual care group from month 3 onward. We define compliance as attending one or more cognitive therapy sessions during the follow-up period of interest. The noncompliance rate of subjects assigned to the cognitive therapy group are 7%, 9%, 36%, and 64% in follow-up periods of one month, three months, six months, and twelve months respectively. Data for the 18 month follow-up are not included in the analysis, because noncompliance rate is 96%.
We apply the proposed Markov compliance and outcome model to the CBT study. We assume relatively flat priors because we do not have strong prior knowledge for the CBT study. Specifically, we letˇ
Inv-2 .1; 1/. Ten is chosen as the variance of prior of Â because it reflects our belief that baseline covariates will not have extreme impacts on the probability of principal stratum membership, without being unduly informative on the probability scale away from 0 and 1. We ran two chains from different starting values, each with 100,000 iterations after a burn-in of 50,000. Our maximum value of O R is 1:02 < 1:1, indicating the Markov chains have indeed converged.
We focus first on the situation where the correlation between the two potential outcomes under treatment and control is high ( D 0:9). Table II shows the estimated CACE and I T T n for cognitive therapy treatment. The results show that for compliers, the cognitive therapy consistently lowers depression severity more effectively than usual care. On average among compliers, the cognitive therapy lowers p BDI 0.63 (95% CI .05,1.27) more than that under usual care at 1 month, and this effect increases to 2.22 (95% CI 1.02,3.35) at 12 months. For not-takers, because they would not participate in the cognitive therapy regardless the group they are assigned, we can view I T T n as the effect of randomization to cognitive therapy without actually taking the therapy. The results show that subjects randomized to cognitive therapy who are unwilling or unable to complete treatment during the first month have average p BDI scores 1.58 (95% CI 0.38,2.90) higher than if they had not been randomized to cognitive therapy. The results imply that being assigned to cognitive therapy -though not cognitive theraphy itself -is harmful to not-takers at the beginning of the study. This effect decreases over time, with the 95% credible interval including 0 from 6 months on. Table II . Cognitive behavior therapy study: intent-to-treat effects in the complier stratum (ITT a or CACE), intent-to-treat effects in the never-taker stratum (ITT n ), overall ITT effects, and as-treated (AT) effects: posterior medians and 95% credible intervals (in parenthesis) at each follow-up time. =assumed correlation among counterfactual potential outcomes. To compare our proposed model with the traditional analysis methods, we show the results of ITT and AT analyses in Table II . For the ITT analyses, we fit a linear mixed model with a random intercept for each subject, with fixed-effect indicators for follow-up periods, treatment assignment, and their interaction. The analysis shows that assignment to cognitive therapy lowers depression severity on average in all follow up periods, although these effects are smaller than the CACE of cognitive therapy, and the CI does not exclude 0 until 6 months. Note that the effect of randomization is different from the effect of cognitive therapy in the CBT study because of the large proportion of noncompliance. For the AT analysis, we use a model similar to that for the ITT analysis but replace treatment assigned with treatment taken. The analysis shows that cognitive therapy lowers depression severity from 6 months after randomization. However, because of self-selection, subjects participating in the cognitive therapy and subjects participating in the usual care might no longer be comparable, and estimates of the effect of cognitive therapy from AT analysis appear to underestimate the CACE.
In Table III , we show the estimated probit regression parameters (elasticities) governing principal compliance in the follow-up period t .t > 1/ when within-subject correlation is assumed to be high ( D :9). The coefficients Â y and Â y C Â yc estimate the impact of the effect of randomization to cognitive therapy among not-takers and compliers respectively at follow-up period t 1 on the probability of being a complier versus a never-taker at follow-up period t . The positive 95% credible intervals indicates that the probability of being a complier at follow up period t increases as the effect of randomization to cognitive therapy at the end of follow-up period t 1 increases. The quantity Â y CÂ yc is larger, indicating this effect is stronger for compliers than not-takers at follow-up period t 1. The parameter Â c shows the effect of being a complier at t 1 on that of being a complier at t among those for whom the treatment assignment was neither harmful nor beneficial. The results show that principal compliance status at time t 1 is not predictive of principal compliance status at time t when the treatment had no effect at time t 1.
The parameters˛g ender and˛B DI measure the impact of baseline covariates on the principal compliance in the first follow-up period. The 95% credible interval of˛B DI is positive (˛B DI = 0.79 (0.47, 0.87)), indicating that the subjects have higher probability of being compliers in the first follow-up period if the subjects have more severe depression at the time of randomization.˛g ender is estimated to be positive, but the 95% credible interval covers zero (˛g ender D 0:62. 0:30; 0:84/), indicating that females tend to be marginally more likely to comply in the first follow-up period. (Results not shown in Table III.) To assess the fit of data, we check the PPD of the principal compliances and potential clinical outcomes. The p values of the PPD of principal compliances are 0.83, 0.69, 0.53, and 0.47 for follow-up periods 1, 3, 6, and 12 months, respectively, indicating a good fit for principal compliance. The Q-Q plot in Figure 3 shows the distribution of the potential clinical outcome test statistics is very close to the model-predicted chi-square distribution with 416 degrees of freedom, indicating that the normality assumption for the transformed BDI measure is reasonable.
Sensitivity to potential outcomes correlations
Because there is no data available to assess the correlation of the potential outcomes, we fix this value at a constant and consider the impact of different values on our inferences of interest. The previous section assumed high correlation ( D 0:9); here we consider a moderate correlation ( D 0:5) or a small correlation ( D 0:1).
The results in Table II imply that both CACE and I T T n are not sensitive to the correlation of the potential outcomes. Under both moderate and small correlations, the cognitive therapy consistently has better effects on lowering depression severity than the usual care for compliers. The magnitudes of the Table III . Posterior medians and 95% credible intervals of probit regression parameters (elasticities) governing the cognitive behavior therapy compliance classes for follow-up period t > 1. = assumed correlation among counterfactual potential outcomes. difference are very similar to those under high correlation of potential outcomes. For not-takers, under both moderate and small correlations, assignment to cognitive therapy makes subjects' depression more severe than assignment to usual care at the beginning of the study. This effect decreases as time increases and disappears at 1 year after randomization. The estimated parameters governing the principal compliance are shown in Table III . The results show that, as the correlation of potential outcomes becomes smaller, the impact of the causal effect of cognitive therapy among not-takers at the previous time period (Â y ) and similarly the impact of the causal effect of cognitive therapy among compliers at the previous time (Â y +Â yc ) shrink toward 0, whereas the impact of being a complier at the previous time (Â c ) expands simultaneously. The variance of the difference of bivariate normal random variables becomes larger as their correlation becomes smaller. Because the treatment effect is the difference of the bivariate random variables, as the correlation of within-subject potential outcomes becomes smaller, the variance of the treatment effect will become larger; thus, the association between the treatment effect and future compliance will become weaker, and other predictors will play a more important role in the model.
Simulation results
Although we utilize a Bayesian framework for our analysis, we are still interested in the repeated sampling properties of our proposed model. To assess this, we simulate 50 datasets of 100 subjects each with four follow-up periods. To make subjects' compliance behaviors and clinical outcomes similar to the CBT study data, each dataset are simulated under˛= (˛0,˛g ender ,˛B DI / = . 3:0; 0:6; 0:8/,ˇ= (ˇ1, 0 ,ˇc 1 ,ˇc 0 / = .3:1; 1:7; 1:2; 3: We analyze the simulated data by using the proposed Markov compliance and outcome model.
We summarize the simulation results of the estimated CACE and I T T n in each follow up-period along with other parameters of interest in Table IV and Table V . Given the modest number of simulations due to the relatively long time necessary to fit the model to a single simulated dataset, very accurate assessments of the repeated sampling properties of our Bayesian model are not possible; however, all parameters appear to have relatively low amounts of bias and either approximately correct coverage or modest undercoverage.
Discussion
In the setting of a two-arm randomized control trial setting, where subjects are randomized at baseline to either treatment or control, and both outcomes and compliance behavior are assessed at multiple time points after baseline, we develop a model by using a principal stratification approach that assesses a both a complier average causal effect for the outcome at each time point as well as an estimate of how previous compliance behavior and causal effects may impact current compliance behavior. This latter aspect of our model is unique in the literature to our knowledge. We apply this model to a CBT study, showing that the stronger the individual-level effect of randomization to cognitive therapy is at the end of follow-up period t , the greater the probability that subjects will be compliers in the follow up period t C1. This association is stronger for compliers than not-takers at time t . Our findings imply that subjects are sensing whether the treatment is effective for them, and adapting their compliance behavior accordingly. It is important to note that this result refers to the unobservable potential effect of the treatment on a given subject. Our proposed model accommodates time-varying latent compliance classes, similar to [7, 9] , and [8] . Our approach differs from [7, 8] , because our proposed model does not have a 'super' principal compliance class, which summarizes the longitudinal pattern of compliance behaviors. There is a trade-off between this superclass approach and the Markovian approach in this manuscript -the former allows one to consider the cumulative impact of compliance behavior in a simple and direct fashion without, however, providing a true complier average causal effect, whereas the latter allows one to both 'unpack' the effect of potential outcomes at time t 1 on compliance at time t , as well as provide a valid interpretation of the causal effect within the complier principal stratum at each follow-up time t among a possibly differing group of compliers at each time point.
In terms of the assumptions, our proposed causal model is different from previous work in a variety of ways. First, we relax the exclusion restriction, which is a common assumption [4] [5] [6] 12] . In the CBT study, the main clinical outcome is depression severity. It is special, because even the randomization to treatment may affect it. The analysis provides evidence that assignment to the cognitive therapy group is harmful for not-takers at the beginning of the study, though this effect eventually disappeared at the end of 1 year. Because avoiding the enrollment of non-compliant individuals can be very difficult, especially in a mental health study, these results emphasize the need to monitor carefully noncompliers for harmful effects of CBT assignment, especially those who are noncompliant with treatment during the early period of the study.
Our research also differs in the way we model the potential outcomes. Previous research typically assumed a location shift between the potential outcomes under treatment and control, as in [13] . Such models assume a perfect correlation between the potential outcomes in all cases. In reality, it is reasonable to consider a correlation between 0 and 1 [19] . As in [19] , we consider the correlation as a sensitivity parameter, and assess the sensitivity of analysis results to this correlation. Our results show that the principal effects are relatively insensitive to the choice of this correlation. There is more sensitivity to the choice of correlation for the prediction of future compliance behavior. If we assume the within-subject correlation of potential outcomes to be high, the effectiveness of the treatment for a given subject is a much more important predictor for future compliance than for previous compliance. If the within-subject correlation of potential outcomes is assumed to be low, then within-subject treatment effectiveness has little association with future compliance, and previous compliance better predicts future compliance. (There is little to guide us on the exact choice of this correlation; although we might assume it is non-negative but less than perfect; perhaps a moderately high assumption in the range of 0.3-0.7 is reasonable, depending on how one conceptualizes the sources of the residual 'within-subject' error unique to each counterfactual outcome.)
We build our Markov compliance class and outcome model on the basis of a single-order Markov relationship. This model has the advantage of clear interpretation of model parameters, and the posterior predictive checks for compliance classes and potential outcomes show that the single order Markov relationship model provides sufficient fit for the CBT study. If fitting a higher order Markov model suggests that this relationship does not hold, for example, if the dependence between the t and t -1 potential outcomes were to differ by treatment assignment, then we need to replace 0 and 1 with 0´a nd 1´, yielding
One could view this model as assuming a sort of second-order failure of the exclusion restriction, namely that treatment assignment by itself affects dependence between the t and t -1 potential outcomes. This seems rather implausible, although even in this situation c1t c0t still encapsulates the difference between the I T T c;t effect and the I T T n;t effect. A more serious situation would be that in which the previous principal stratum membership still carries information about the I T T effect even after conditioning on the current principal stratum membership and the previous potential outcomes. In this setting, the principal strata at time t would be defined in terms of vectors of principal strata, for example, f.S i;t 1 D c; S it D c/; .S i;t 1 D c; S it D n/; .S i;t 1 D n; S it D c/; .S i;t 1 D n; S it D n/g if a one-degree Markov relationship with principal compliance held. Simple causal interpretation of these strata is no longer possible. If this is the case, alternative approaches such as those developed in [7, 8] that use a clustering algorithm to develop relatively interpretable strata such as high or low compliers may be used, at the cost of both clean causal interpretability of the principal stratum treatment effect, as well as the ability to estimate the link between the previous causal treatment effect and current compliance behavior. We also note that estimating such higher-order Markov models will likely require large sample sizes to obtain stable estimates of effects.
Other extensions of the approach developed here are possible. The mixture model for the potential outcomes is not nonparametrically identified in the absence of the exclusion restriction assumption [20] . Although allowing for the exclusion restriction would provide for nonparametric identification, such an assumption may not be warranted in this setting, where the act of noncompliance on the treatment arm may have an effect on mental states that would not occur if assigned to the control arm. Instead, we rely on the normality assumption to identify the mixture components associated with the complier and not-taker groups in the control arm. Although the marginal distributions of Y i .1/ and Y i .0/ appear approximately normally distributed, the assumption of joint normality conditional on compliance stratum cannot be assessed, given that complier status is partially latent and that only one on of the potential outcomes is observed. An alternative to this approach would be to weaken or eliminate this parametric assumption and rely on either observed predictors of compliance [21] or prior distributional assumptions to induce posterior modes. Assessing the effect of departures from the normality assumption in these longitudinal potential outcome models remains an open research area. 
